Results 171 to 180 of about 1,341 (183)

Development of a rezafungin isolate verification panel and comparison of reference method to ThermoFisher Sensititre YeastOne panel MIC results.

Diagnostic microbiology and infectious disease
Rezafungin is indicated for the treatment of adults with limited or no alternative treatment options for candidemia and invasive candidiasis. The development of a rezafungin isolate verification panel is described.
J. DiFranco-Fisher, L. Koeth
semanticscholar   +1 more source

Regulatory Considerations in the Approval of Rezafungin (REZZAYO) for the Treatment of Candidemia and Invasive Candidiasis in Adults.

Journal of Infectious Diseases
On March 22, 2023, the FDA approved rezafungin (REZZAYO) for the treatment of candidemia and invasive candidiasis in adults with limited or no alternative treatment options.
H. Smith, Timothy J Bensman, Shrimant Mishra, Xianbin Li, Cheryl Dixon, Jalal Sheikh, Owen McMaster, A. Joshi, Daniel B Rubin, Avery C. Goodwin, Terry J Miller, Z. Y. Danielsen, Irum Syed, Sunita J Shukla, Dmitri Iarikov, Peter Kim, John J Farley   +16 more
semanticscholar   +1 more source

Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy)

Antimicrobial Agents and Chemotherapy
Rezafungin is an echinocandin characterized by a long elimination half-life which allows for weekly administration. It has been recently approved for the treatment of candidemia.
G. Ponta, V. Morena, Martina Strano, C. Molteni, S. Pontiggia, E. Cavalli, Anna Grancini, Carola Mauri, Antonella Castagna, Andrea Galanti, S. Piconi   +10 more
semanticscholar   +1 more source

An evaluation of Rezafungin: the latest treatment option for adults with candidemia and invasive candidiasis

Expert Opinion on Pharmacotherapy
Introduction Invasive fungal infections, especially candidemia and invasive candidiasis, continue to cause substantial morbidity and mortality. In addition, the emergence of drug-resistant Candida species, notably C. glabrata and C.
Divisha Sharma, Jose A Vazquez
semanticscholar   +1 more source

Rezafungin Acetate

American Journal of Health-System Pharmacy, 2023
openaire   +2 more sources

Clinical and mycological outcomes of candidaemia and/or invasive candidiasis by Candida spp. and antifungal susceptibility: pooled analyses of two randomised trials of rezafungin versus caspofungin.

Clinical Microbiology and Infection
OBJECTIVES A post hoc analysis used pooled STRIVE/ReSTORE trial data to determine outcomes with rezafungin versus caspofungin by Candida species and antifungal susceptibility.
Á. Soriano, J. B. Locke, Oliver A. Cornely, E. Roilides, A. Ramos-Martínez, P. Honoré, M. Castanheira, C. Carvalhaes, S. Nseir, Matteo Bassetti, Nick Manamley, T. Sandison, M. Arendrup   +12 more
semanticscholar   +1 more source

Rezafungin acetate. 1,3-beta-Glucan synthase inhibitor, Antifungal agent

Drugs of the Future, 2020
null Chopra, S., null Thakare, R., null Dasgupta, A.   +2 more
openaire   +1 more source

New antifungals development: rezafungin in candidiasis treatment

The Lancet Infectious Diseases
Desnos-Ollivier, Marie, Lanternier, Fanny   +1 more
openaire   +3 more sources

Rezafungin and invasive candida infections: a new game changing antifungal?

The Lancet, 2023
openaire   +2 more sources

Safety Study of Rezafungin to Treat Invasive Fungal Infections

Case Medical Research, 2019
openaire   +1 more source